Treatment Adherence Clinical Trial
— CerinaOfficial title:
Cerina- Cognitive Behavioural Therapy Based Mobile Application for Managing GAD Symptoms: A Pilot Randomized Controlled Trial
The goal of this pilot Randomized Controlled Trial is twofold: 1) To learn about the feasibility and usefulness of a mobile application for generalised anxiety symptoms (Cerina); 2) To test the preliminary effects of Cerina in reducing generalized anxiety symptoms compared to a waitlist-control group among Ulster University students presenting mild to moderate symptoms of Generalized Anxiety Disorder (GAD) symptoms. The main research questions are: Is the Cerina app usable and feasible among Ulster University students reporting mild to moderate GAD symptoms? Is there an indication of the effectiveness of the Cerina app in reducing GAD symptoms compared to a wait-list control group among Ulster University students? - After the baseline assessment, eligible and consenting participants will be randomized to either intervention or to the wait-list control group. - Those who are allocated to the intervention group will have access to the Cerina app for 6 weeks. - Those who are in the wait-list control group will wait for 6 weeks until the intervention group finishes the intervention for their access. - The wait-list control group will have access to the services offered by the Ulster University Student Wellbeing team. - Participants in both groups will do mid- (at week 3 after their randomization) and post-assessment (At week 6 after their randomization). - All participants will also be invited to the post-assessment feedback interviews once they complete their post-assessments. The purpose is to have more in-depth information on their views of the Cerina app, the User Interface, the clinical content, the potential facilitators, and barriers to using it in daily life.
Status | Recruiting |
Enrollment | 90 |
Est. completion date | August 31, 2024 |
Est. primary completion date | April 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Having mild to severe self-reported anxiety symptoms. Those who score between 5 and 19 on the GAD7 questionnaire will be accepted as eligible, , - 18 years of age and older - Enrolled as a student at Ulster University (i.e. having a student id number) - Fluency in English - Provision of an informed consent - Having a smartphone (i.e. Android device or iPhone). - Having an internet connection Exclusion Criteria: - Having minimal anxiety symptoms as defined by a score of 5 and below on the GAD7 questionnaire - Scoring 19 and above on the GAD7 questionnaire - Having self-reported suicidal thoughts based on their scores on the Patient Health Questionnaire-9 (PHQ9). - Having recently (within the last 6 weeks) started taking psychotropic medication. - Not consenting that their contact details (name, surname, email address) will be shared with the Student Wellbeing team (see the safety section) - Receiving psychological treatment is not part of the exclusion criteria. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Ulster University | Belfast |
Lead Sponsor | Collaborator |
---|---|
Cerina Therapeutics | European Commission, University of Ulster |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Generalised Anxiety Disorder Scale-7 (GAD-7) | GAD-7 is a 7-item self-report scale that identifies and measures the severity of GAD. Scores range from 0 to 21, with a cut-off score of 5 distinguishing between clinical and non-clinical populations. The scale has good psychometric properties | baseline, week 3 and week 6 | |
Secondary | The Penn State Worry Questionnaire (PSWQ-PW) | PSWQ-PW is a 15-item inventory assessing both the weekly status of pathological worry and treatment-related changes of worry during the treatment (Stöbber & Bittencourt, 1998). Each item is scored on a 7-point rating scale, ranging from never 0 (never) to 6 (almost always). The total score ranges from 0 to 90 with a high score indicating more worrying. PSWQ-PW shows good reliability and convergent validity | baseline, week 3 and week 6 | |
Secondary | The Patient Health Questionnaire (PHQ-9) | PHQ-9 is a 9-item self-report scale that measures depression symptoms. Scores range from 0 to 27, with a score of 10 and above considered to be a clinically significant level of depression. The PHQ-9 has good reliability and validity | baseline, week 3 and week 6 | |
Secondary | The Work and Social Adjustment Scale (WSAS) | WSAS is a 5 item self-report measure that assesses functional impairment. Scores range from 0 to 40. The scale assesses the impact on work, home, social and private activities, and personal and family relationships. A score 20 and above is considered to indicate severe functional impairment, scores between 10 and 20 suggest severe but functional impairment, and scores of 10 and less are considered subclinical. The scale has good reliability and validity | baseline, week 3 and week 6 | |
Secondary | Usability | The System Usability Scale (SUS) is composed of 10 statements that are scored on a 5-point scale of the extent of agreement (score 0 to 100). The reliability is good (Cronbach's alpha 0.91). Interventions with scores of 70 and above are accepted as highly usable (Bangor et al., 2008) and scores between 50 and 70 indicate acceptable usability of an intervention. Interventions with scores of 50 and below are subject to concerns about their usability by the target population and should be investigated further. Additionally, semi-structured interviews will be conducted with the users to have more in-depth understanding of the usability of the Cerina app in real life. | week 3 and week 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04573465 -
Pilot Evaluation of Peer-support Coaching to Increase Adherence to Online Self-help for College Mental Health
|
N/A | |
Withdrawn |
NCT05566015 -
Relationship Between Self-compassion and Treatment Adherence in Schizophrenic Spectrum Disorders
|
N/A | |
Enrolling by invitation |
NCT06070415 -
Adherence to Exercises for Low Back Pain.
|
N/A | |
Completed |
NCT04464421 -
SMART Effectiveness Trial
|
N/A | |
Completed |
NCT04323215 -
Evaluation of a Digital Childhood Obesity Treatment
|
||
Completed |
NCT06434259 -
Evaluation of Long-term Digital Childhood Obesity Treatment
|
||
Completed |
NCT05022706 -
Pilot Study of a Transition Intervention for ALWH
|
N/A | |
Recruiting |
NCT05084625 -
PACED-digitized Support During Adjuvant Endocrine Therapy
|
N/A | |
Completed |
NCT04377321 -
Colchicine Has Anti-diabetic Effect
|
||
Enrolling by invitation |
NCT06115538 -
Comparison of Dopamin Level in Idiopathic Parkinson's Patients
|
Phase 4 | |
Completed |
NCT03842384 -
Digital Health Intervention to Support Opioid Use Disorder Treatment
|
N/A | |
Recruiting |
NCT05869461 -
Improving HIV Adherence Care for Key Populations in India
|
N/A | |
Active, not recruiting |
NCT04221789 -
TB Treatment Support Tool Interactive Mobile App and Direct Adherence Monitoring on TB Treatment Outcomes
|
N/A | |
Recruiting |
NCT05825807 -
Adherence to Pharmacological Antiepileptic Treatment in Adolescence
|
||
Active, not recruiting |
NCT04166422 -
Virtual Reality and Video Games in Cardiac Rehabilitation Programs
|
N/A | |
Active, not recruiting |
NCT04166617 -
Assessment Effectiveness of the Leap Motion Capture® System on the Functionality of the Upper Limb in Acquired Brain Injury
|
N/A | |
Completed |
NCT04171908 -
Semi-inmersive Virtual Reality on Upper Limb in Multiple Sclerosis
|
N/A | |
Completed |
NCT04117750 -
Impact of Vitamin D Supplementation on Cardiometabolic Status and Androgen Profile in Polycystic Ovary Syndrome
|
N/A | |
Enrolling by invitation |
NCT05321641 -
Evaluation Of A Mobile Messaging Service In Improving Adherence Of Anti-Seizure Medications
|
N/A | |
Active, not recruiting |
NCT05907174 -
Siyakhana Peer: Evaluating a Peer Recovery Coach Model to Reduce Substance Use Stigma in South African HIV Care
|
N/A |